untitled
<OAI-PMH schemaLocation=http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd>
<responseDate>2018-01-15T18:31:05Z</responseDate>
<request identifier=oai:HAL:hal-01121799v1 verb=GetRecord metadataPrefix=oai_dc>http://api.archives-ouvertes.fr/oai/hal/</request>
<GetRecord>
<record>
<header>
<identifier>oai:HAL:hal-01121799v1</identifier>
<datestamp>2017-12-21</datestamp>
<setSpec>type:ART</setSpec>
<setSpec>subject:sdv</setSpec>
<setSpec>collection:UNIV-RENNES1</setSpec>
<setSpec>collection:UNIV-AG</setSpec>
<setSpec>collection:IFR140</setSpec>
<setSpec>collection:IRSET</setSpec>
<setSpec>collection:IRSET-VCER</setSpec>
<setSpec>collection:BIOSIT</setSpec>
<setSpec>collection:UR1-UFR-SVE</setSpec>
<setSpec>collection:STATS-UR1</setSpec>
<setSpec>collection:UR1-SDV</setSpec>
<setSpec>collection:UR1-HAL</setSpec>
<setSpec>collection:EHESP</setSpec>
<setSpec>collection:USPC</setSpec>
<setSpec>collection:IRSET-8</setSpec>
<setSpec>collection:UNIV-ANGERS</setSpec>
<setSpec>collection:IRSET-EHESP</setSpec>
</header>
<metadata><dc>
<publisher>HAL CCSD</publisher>
<title lang=en>Antiviral inhibition of enveloped virus release by tetherin/BST-2: action and counteraction.</title>
<creator>Le Tortorec, Anna</creator>
<creator>Willey, Suzanne</creator>
<creator>Neil, Stuart J D</creator>
<contributor>Institut de recherche, santé, environnement et travail [Rennes] (Irset) ; Université d'Angers (UA) - Université des Antilles et de la Guyane (UAG) - Université de Rennes 1 (UR1) - École des Hautes Études en Santé Publique [EHESP] (EHESP) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )</contributor>
<contributor>Department of Infectious Diseases ; King's College London School of Medicine</contributor>
<description>International audience</description>
<source>ISSN: 1999-4915</source>
<source>EISSN: 1999-4915</source>
<source>Viruses</source>
<publisher>MDPI</publisher>
<identifier>hal-01121799</identifier>
<identifier>https://hal-univ-rennes1.archives-ouvertes.fr/hal-01121799</identifier>
<source>https://hal-univ-rennes1.archives-ouvertes.fr/hal-01121799</source>
<source>Viruses, MDPI, 2011, 3 (5), pp.520-40. 〈10.3390/v3050520〉</source>
<identifier>PUBMED : 21994744</identifier>
<relation>info:eu-repo/semantics/altIdentifier/pmid/21994744</relation>
<identifier>DOI : 10.3390/v3050520</identifier>
<relation>info:eu-repo/semantics/altIdentifier/doi/10.3390/v3050520</relation>
<identifier>PUBMEDCENTRAL : PMC3185764</identifier>
<language>en</language>
<subject>[SDV] Life Sciences [q-bio]</subject>
<type>info:eu-repo/semantics/article</type>
<type>Journal articles</type>
<description lang=en>Tetherin (BST2/CD317) has been recently recognized as a potent interferon-induced antiviral molecule that inhibits the release of diverse mammalian enveloped virus particles from infected cells. By targeting an immutable structure common to all these viruses, the virion membrane, evasion of this antiviral mechanism has necessitated the development of specific countermeasures that directly inhibit tetherin activity. Here we review our current understanding of the molecular basis of tetherin's mode of action, the viral countermeasures that antagonize it, and how virus/tetherin interactions may affect viral transmission and pathogenicity.</description>
<date>2011-04-30</date>
</dc>
</metadata>
</record>
</GetRecord>
</OAI-PMH>
